WO2006013069A2 - Verfahren und mittel zur gewinnung von thrombocytenreichem plasma - Google Patents
Verfahren und mittel zur gewinnung von thrombocytenreichem plasma Download PDFInfo
- Publication number
- WO2006013069A2 WO2006013069A2 PCT/EP2005/008252 EP2005008252W WO2006013069A2 WO 2006013069 A2 WO2006013069 A2 WO 2006013069A2 EP 2005008252 W EP2005008252 W EP 2005008252W WO 2006013069 A2 WO2006013069 A2 WO 2006013069A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- plasma
- thrombocyte
- rich
- vessel
- platelet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/029—Separating blood components present in distinct layers in a container, not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/04—Surgical adhesives or cements; Adhesives for colostomy devices containing macromolecular materials
- A61L24/10—Polypeptides; Proteins
- A61L24/108—Specific proteins or polypeptides not covered by groups A61L24/102 - A61L24/106
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
- A61M1/3693—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits using separation based on different densities of components, e.g. centrifuging
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/02—Blood transfusion apparatus
- A61M1/0209—Multiple bag systems for separating or storing blood components
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0415—Plasma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/04—Liquids
- A61M2202/0413—Blood
- A61M2202/0427—Platelets; Thrombocytes
Definitions
- the present invention relates to methods and compositions for the capture of thrombocyte-rich plasma ("platelet rich pJasma", PRP), which has a high content of platelets and which in particular is easily gellable, from whole blood.
- thrombocyte-rich plasma platelet rich pJasma
- PRP platelet rich pJasma
- Platelet-rich plasma is used in medicine, among others, in the treatment of wounds, for the support of bone healing, for haemostasis, in particular in plastic surgery, etc.
- the preparation and the use of autologous thrombocyte-rich plasma from whole blood is Foreground.
- Thrombocytes in thrombocyte-rich plasma are characterized in particular by their high content of proteins, in particular growth factors and cytokines, which can be released from the thrombocytes with appropriate treatment.
- the growth factors and cytokines are essentially platelet derived growth factor (PDGF), transforming growth factor (TGF), vascular endothelial growth factor (VEGF) and epithelial growth factor (EGF).
- PDGF platelet derived growth factor
- TGF transforming growth factor
- VEGF vascular endothelial growth factor
- EGF epithelial growth factor
- the medicinal benefit of autologous thrombocyte-rich plasma besides being a rich source of various healing promoting growth factors and cytokines, is the promotion of accelerated wound healing in all tissues, the promotion of higher collagen concentration in healing wounds leads in particular to higher scar strength, in the promotion of accelerated Gefäßneubil ⁇ tion, in promoting a reduced bone maturation period, in the promotion of an increased local bone density, in the promotion of partially reduced postoperative pain and in the promotion of lower wound infection rates.
- the risk of transmission of the disease from foreign organisms is also eliminated when obtaining the thrombocyte-rich plasma from autologous whole blood.
- a known technique for obtaining thrombocyte-rich plasma from whole blood is described in WO 00/61265 and in WO 01/83068 of Harvest Technologies Co., using a device with two communicating vessels and for the preparation of the platelet-rich plasma the first vessel is filled with withdrawn whole blood, an erythrocyte-rich pellet is automatically centrifuged, and a plasma supernatant containing the platelets is automatically separated therefrom by the arrangement of a swimmer within the vascular system during centrifugation. A fluctuating hematocrit can not be compensated.
- a thrombocyte-rich fraction In a second centrifugation step, plasma and a thrombocyte-rich fraction are separated from one another, and then the plasma supernatant is partially removed and the thrombocyte pellet resuspended in a remaining plasma fraction in order to obtain a thrombocyte-rich plasma.
- the known technologies and methods for obtaining autologous thrombocyte-rich plasma can not provide a constant and high yield and quality.
- the fluctuations in yield and quality are due to the variability of the hematocrit of the removed whole blood.
- the hematocrit that is to say the volume fraction of the cellular constituents of the total volume of the whole blood, can vary considerably between individuals, for example from 35 to 50%.
- the existing systems for producing fresh platelet concentrates are unable to compensate for this variability of hematocrit. Consequently, the quality of the final product varies considerably with respect to the yield and the quality of the thrombocyte-rich plasma obtained.
- thrombocyte-rich plasma autologously and, if possible, on-site and freshly, as well as under always sterile conditions, with the same constant yield. It is also desirable to obtain a high-quality platelet-rich plasma which forms a large amount of useful proteins such as growth factors and cytokines and has a high content of platelets.
- thrombocyte-rich plasma is increasingly being used as a coagulated thrombocyte-rich gel for a number of applications.
- the mechanical strength of the gel is crucial for its effectiveness and effectiveness in this application. It turns out, however, that the thrombocyte-rich plasma obtainable by known methods also has a low quality with respect to its coagulability. It is therefore also desirable to obtain thrombocyte-rich plasma which has a high coagulability and can be coagulated to form a platelet-rich gel which can be used more readily.
- the technical problem underlying the present invention consists essentially in providing a method and means for obtaining thrombocyte-rich plasma from whole blood, which overcomes the disadvantages of the prior art, wherein the thrombocyte-rich plasma obtained is rich in, in particular activated, Thrombocytes and / or improved coagulability has.
- the present invention is achieved according to the invention by providing a method for obtaining platelet-rich plasma from whole blood, wherein in a first step a) the whole blood is separated into at least one erythrocyte-containing fraction and a plasma fraction containing the thrombocytes ent and essentially erythrocyte-free, in a second step b) the thrombocyte-containing plasma is separated from the erythrocyte-containing fraction, in a further step c) the thrombocyte-containing plasma, preferably by centrifugation, into a thrombocyte-containing fraction which is preferably adjacent
- the platelets also nucleated cells, ie, buffy coat and / or in particular is present as a pellet, wherein preferably immediately above the pellet formed further thrombocytes are suspended in the plasma, and in a supernatant from low platelet plasma separated w
- the supernatant obtained from thrombocyte-poor plasma preferably by means of a syring
- the inventors found, surprisingly, that a significantly increased thrombocyte activation takes place in particular by the reapplication of plasma supernatant previously removed and mixed after removal.
- the inventors further found, surprisingly, that a thrombocyte-rich plasma which has a markedly improved coagulability is obtained, in particular by the re-application of previously removed plasma supernatant mixed after removal. Without being limited to theory, this effect may possibly be due to the fact that the platelets are resuspended in a plasma containing all plasma components, high molecular weight and low molecular weight, in physiologically correct composition.
- the coagulation factors important for the subsequent coagulation are also contained in the thrombocyte-rich plasma obtained in accordance with the invention, as a result of which it can be more easily coagulated and a more improved platelet-rich gel can be obtained.
- the known methods do not achieve this because only a part of the plasma is removed from the supernatant to obtain a thrombocyte-rich plasma, while a plasma residue containing especially high molecular weight fractions is mixed with the thrombocyte fraction.
- the invention provides that, in particular autologous, and in particular venous, whole blood is taken from a patient and immediately afterwards from this blood at least one erythrocyten-rich fraction of the thrombocytes and preferably the "buffy coat" containing plasma, that is from at least one predominantly platelet and mononuclear cells are contained. separated fraction.
- the in a vessel, in particular elastic vessel, preferably an elastic bag introduced whole blood by centrifugation, preferably at from 1500 to 3500 revolutions per minute, preferably from 2000 to 2800 revolutions per minute, over a preferred period of 1, 5 separated up to 4 minutes and in the vessel an erythrocyte-rich, especially erythrocyte-containing fraction as a pellet at the bottom of the vessel and at least one thrombocytes and preferably mononuclear cells containing "buffy coaf fraction obtained as a supernatant.
- erythrocyte-rich especially erythrocyte-containing fraction as a pellet at the bottom of the vessel and at least one thrombocytes and preferably mononuclear cells containing "buffy coaf fraction obtained as a supernatant.
- At least three fractions are formed: an erythrocyte-containing fraction which appears red, a thrombocyte-containing buffy coaf fraction which appears as a white, viscous and thin layer, and a supernatant of plasma appearing from yellow to orange.
- the whole blood fractionated in the vessel, in particular the elastic bag, by centrifugation is mechanically applied by rolling up and / or wiping the vessel such that the plasma supernatant together with the thrombocyte-containing buffy coat fraction , which are in the upper portion of the vessel, is pressed out of the first vessel and in particular via a transfer line, which is connected to a second vessel, in particular an elastic vessel, in particular an elastic bag, is transferred to this, wherein the erythrocyte-containing fraction is separated as a function of the hematocrit of the removed whole blood.
- the adaptation preferably takes place in that the extrusion of the supernatant from the first vessel, in particular by rolling up and or Streaking is continued until one of the plasma supernatant is largely transferred and the erythrocyte-containing fraction, ie the erythrocyte-containing pellet, is located at the upper end of the vessel.
- the beginning of an erythrocyte-containing fraction, and thus the end of the transfer process can be determined by the appearance of erythrocytes at the upper end of the first vessel and / or detect in the transfer line.
- the invention makes use of the properties of erythrocytes, in particular to absorb light energy in the visible range of the light, in particular by reddening to blushing.
- the presence of erythrocytes at the upper end of the first vessel and / or in the transfer line is inventively preferably detected by suitable detectors or counters in a conventional manner and / or by simple visual inspection and then the transfer process ge stops. In this way, according to the invention, it is advantageously achieved that, in any case and independently of the individual hematocrit present, the largest possible amount of thrombocytes is obtained from the whole blood.
- controlled transfer therefore means the process of transferring the supernatant from thrombocyte-containing plasma from centrifuged, fractionated whole blood which, depending on the individual hematocrit of the whole blood used, is the process of transferring the plasma supernatant
- tion of an erythrocyte-containing fraction is preferably characterized in that a detectable fraction of erythrocytes is present at the upper end of the first vessel and / or in the transfer line. It is preferred to transfer all thrombocytes to the second vessel as a particularly pure, that is to say free from erythrocyte, platelet fraction.
- the invention further provides that in further process steps the transferred and separated from the erythrocyte-containing fraction th thrombocyte-containing plasma preferably by centrifugation at from 2900 to 5000 revolutions per minute, preferably from 3200 revolutions per minute, over a period of 10 to 20 minutes, preferably 15 minutes, into a platelet fraction which, preferably together with monocular cells, is present in particular as a pellet and is fractionated into a thrombocyte-poor plasma supernatant.
- thrombocyte-poor plasma in particular via an opening in the upper section of the second vessel, in particular the elastic bag, in which the separation of the thrombocyte-containing plasma has taken place, entnom ⁇ men, so that, preferably present as a pellet, thrombocyte tenfr forcing in the second vessel remains.
- the thrombocyte-poor plasma is completely and / or substantially completely removed.
- up to 90%, 80%, 70%, 60%, 50%, 20%, 10% of the thrombocyte ⁇ narmen plasma are removed.
- the thrombocyte-poor plasma is removed in an amount that is selected as a function of the individual hematocrit of the whole blood used.
- the plasma is stratified, ie in particular in the upper part of the plasma are small components and in the lower part of the plasma are larger components, is now, as in known methods, after centrifugation only When the upper part of the plasma is removed, the plasma remaining with the platelet fraction is unnaturally enriched in high-molecular constituents.
- the withdrawn thrombocyte-poor plasma preferably in the means used for the removal, in particular a syringe, is mechanically mixed.
- the plasma constituents separated by the preceding centrifugation mix again, so that a largely physiological composition of the plasma is established, that is, a plasma is obtained which is a homogeneous composition of naturally occurring plasma having.
- the withdrawn and mixed thrombocyte-term plasma is returned to the thrombocyte fraction, ie in particular into the second vessel containing the thrombocyte fraction, that is to say reapplied, and subsequently the thrombocyte fraction is mixed with the returned plasma and thereby resuspended.
- the resuspension preferably takes place by mechanical mixing of the thrombocyte fraction from the reapplied plasma.
- the resuspension is carried out in the second vessel, which is preferably designed as an elastic bag, wherein the contents of the second vessel are mixed by preferably manual, mechanical loading of the elastic vessel walls, in particular by massaging.
- the mechanical stress of the mechanically sensitive thrombocytes is reduced to a minimum, which promotes the recovery of a particular rich in activated platelet plasma.
- the plasma which is particularly rich in activated thrombocytes, is then recovered by transferring or resuspending the platelet fraction resuspended in the reapplied thrombocyte poor plasma.
- a coagulant that is to say a coagulant
- the formation of this gel is strongly promoted by the fact that the appropriate concentration and the appropriate ratio of all relevant coagulation factors, which are naturally present in the plasma, are present in the thrombocyte-rich plasma obtained according to the invention.
- Both the thrombocyte-rich plasma obtained according to the invention and the thrombocyte-rich gel preferably obtained according to the invention have a markedly increased formation or concentration of proteins such as growth factors and / or cytokines in the contained thrombocytes compared with the thrombocyte-rich plasma obtained by known methods.
- proteins such as growth factors and / or cytokines in the contained thrombocytes
- thrombocyte-rich plasma obtained by known methods In particular, depending on the quality of the thrombocytes obtained and / or the coagulum, there is a burst of thrombocytes, whereby the growth factors or cytokines are released during gel formation.
- the following growth factors or cytokines are formed in the thrombocyte-rich plasma obtained according to the invention and in particular in the thrombocyte-rich gel obtained therefrom:
- TNF-.alpha. and IL-1 ⁇ are inflammatory markers, whereas they are hardly elevated.
- the present invention therefore also relates to the plasma produced in particular by the method according to the invention, in particular to activated thrombocytes, and the gel formed therefrom, in particular by coagulation with a coagulant.
- the thrombocyte-rich plasma or gel obtained according to the invention is used for the prophylaxis and / or therapy or cure of a large number of diseases.
- the thrombocyte-rich plasma or gel according to the invention particularly advantageously has a high leucocyte concentration, this is preferably used in order to reduce the risk of infection in the treatment. Furthermore, the thrombocyte-rich plasma or gel according to the invention particularly advantageously has a high concentration of dendritic cells.
- the inventors further found, surprisingly, that the thrombocyte-rich plasma or gel obtained according to the invention, when mixed with, for example, autologous bone chips and / or bone substitutes, for example hydroxyapatite, gives a particularly advantageous "putty" for filling and / or restoring bone defects.
- a further subject of the present invention is therefore also the use of the invention according to obtained thrombocyte-rich plasma or gel for filling or restoration of bone defects in conjunction with bone chips and / or bone substitutes.
- the thrombocyte-rich plasma or gel obtained according to the invention accelerates the formation of intercellular matrix, which, for example, leads, particularly advantageously, to earlier wound closure.
- a further subject of the present invention is therefore also the use of the thrombocyte-rich plasma or gel according to the invention for accelerating the wound closure.
- the clinical fields of application of the method according to the invention and of the thrombocyte-rich plasma or gel obtainable according to the invention are manifold. They include oral and maxillofacial surgery, orthopedics, plastic and reconstructive surgery and dermatology.
- An object of the present invention is also the use of the thrombocyte-rich plasma or gel according to the invention for accelerating and / or promoting the healing of diabetic ulcerations, in particular on the lower extremities.
- the present invention therefore also relates to the use of the thrombocyte-rich plasma and / or gel according to the invention for accelerating the regeneration of bones, cartilage defects, endothelium, epithelium and / or epidermis; for stimulation of neovascularization; to enhance collagen synthesis; for accelerating the healing of soft tissues; to reduce scar formation; to facilitate hemostasis; to alleviate and / or reverse the negative effects of corticosteroids on wound healing; when filling cartilage defects in auto ⁇ logen cartilage transplantation (ACT), where a matrix with cartilage cells is glued to the defect, or the use of said plasma or gel for the preparation of corresponding pharmaceutical preparations.
- ACT auto ⁇ logen cartilage transplantation
- Vorrich ⁇ device in particular a bag system, which can be preferably used to carry out the method according to the invention.
- This comprises at least one primary vessel (10) and at least one secondary vessel (30), which form a communicating vascular system.
- Primary vessel (10) and secondary vessel (30) are connected via at least one, in particular closable, transfer line (20).
- a "primary vessel” is understood to mean a vessel, that is to say a vessel, in which the liquid or suspension to be separated into its individual components is introduced or is present and subjected to a first fractionation Vessel, that is to say containers, in which the liquid or suspension completely or partially separated into its individual components in the primary vessel is introduced completely or partially, that is to say individual fractions thereof, and this is subjected to a second fractionation in the secondary vessel.
- each of these vessels is provided with at least one, in particular closable, supply and / or supply line (11, 31), in particular for the supply, that is to say introduction or reapplication, of blood components and / or removal, that is to say, removal, provided by blood components.
- primary vessel (10), secondary vessel (30) and transfer line (20) are fixed to a support plate (60).
- the transfer line (20) can be closed by at least one interruption (21), which can be designed as a valve, tap and / or plug.
- the transfer line (20) is designed as an elastic hose and in particular by at least one interruption (21) as a clamp, in particular a hose clamp, or as a slide clamping the hose, which preferably on the support plate (60 ) is arranged, lockable.
- the transition (20) is optically transmissive, that is to say transparent, preferably optically clear, in order to permit the optical control of the transfer of erythrocytes by means of technical means and / or visual control.
- the transition (20) is equipped with an optical detector or counter for detecting the presence of erythrocytes in the Kochlei ⁇ device.
- Both primary vessel (10) and secondary vessel (30) are preferably designed according to the invention as elastic bags.
- These bags are each preferably formed in a "pear shape" which is formed from a substantially semicircular lower portion (14, 34) and upwardly tapered substantially funnel-shaped upper portion (15, 35)
- these elastic pouches are designed as pouches produced by welding and / or gluing elastic foils, normally initially flat, in which the bonded foils are preferably in abutment with one another, and the pouches with a purposeful filling of the between the joined foils lumens usually assume characteristic bag shape.
- the secondary vessel (30) is further characterized in that at least one riser pipe (40) projecting into the lumen of the secondary vessel and having at least one lower opening (42) is provided to the at least one supply and / or supply line of the secondary vessel.
- which is formed at the preferably in the middle of the Sekundärge ⁇ vessel, preferably at the boundary between a sch Vietnameseförmi ⁇ gene lower portion (34) and a funnel-shaped upper portion (35) of the secondary vessel, and at least one upper opening (41) which is formed in the upper section of the secondary vessel, preferably at the upper tip of the funnel-shaped upper part of the secondary vessel, in particular at the attachment of the supply and / or supply line (31) to the inside of the vessel wall of the secondary vessel.
- the inventive design of the primary and Sekundärgefä ⁇ ßes in a pimple-like shape, that is, with an upwardly tapering funnel-shaped upper portion and a rud ⁇ circular lower portion is inventively advantageously an improved control of the separation of erythrocytes of thrombocyte-containing "buffy coat"
- the pear shape according to the invention has the result that the border between erythrocytes, buffy coat and supernatant plasma can be reproduced sharply and clearly.
- preferred transfer of the plasma supernatant from the primary vessel (10) via the transfer line (20) into the secondary vessel (30) is preferably centrifuged a further time to obtain a thrombocyte fraction and a platelet-poor plasma supernatant.
- the inventively preferred pear shape of the secondary vessel (30) allows a particularly favorable because even distribution of Einwir ⁇ effect of centrifugal forces on the platelets per volume fraction, whereby the need for effective fractionation of the blood components not ⁇ speed and centrifugation time can be minimized, resulting in a lower mechanical stress on the platelets leads.
- the device according to the invention for centrifugation is inserted into a centrifuge cup, which is designed in such a way that the primary vessel and / or secondary vessel, which is preferably designed as an elastic bag, is stretched during centrifugation so that the vessel walls become partially and / or completely come to rest on the inner wall of the centrifuge cup.
- a centrifuge cup Preference is given to the use of a sterile cup. Be particularly advantageous so the strain load of the vascular walls and the cells contained during centrifugation redu ⁇ ed.
- the preferred use of a centrifuge cup also allows the use of mechanically lighter, thinner and less stable material for the present invention preferred elastic see-bag.
- the advantage of the lighter and thinner material is also that the mixing, that is, resuspension, of the platelets with the added plasma is easier.
- primary vessel and secondary vessel of the device according to the invention are made of a material which, because of its surface condition and its chemical composition, is particularly advantageous for the coagulability of the thrombocyte-rich plasma obtained by means of the device.
- the focus here is on maximum activation of the platelets without prematurely triggering coagulation.
- the riser pipe (40) with an upper opening (41) and a lower opening (42), which is assigned to the secondary vessel (30) and its at least one inlet / outlet (31) according to the invention, makes it possible to carry out the practically complete removal or removal.
- se complete emptying of the secondary vessel by a majority of the Matterstan ⁇ obtained after centrifugation in the secondary vessel of the first projecting through the lower opening of the secondary vessel into the lumen of Se ⁇ secondary vessel riser is removed and then the last remainder after turning the Secondary vessel, so that the upwardly tapering tip of the secondary vessel is facing down, through the upper opening (41), which is located at the top of the tapered portion of the secondary vessel, can be removed.
- the device according to the invention also permits the recovery of other blood components, such as serum, erythrocyte concentrate, buffy coat or mononuclear cell concentrate, as well as thrombocyte-poor plasma Moreover, the device is also suitable for separating other tissue or body fluids containing, in particular, cellular components
- the device according to the invention can also be used to fractionate all types of cell suspensions, for example cultured mammalian cells, into their constituents and to separate the fractions, for example cell constituents, high molecular weight proteins, etc.
- the device according to the invention permits this Preferably, the optical control in the separation of cellular from non-cellular or other cellular components.Also provided, various Zellbe ⁇ constituents of a cell suspension or a cellular components to mark containing liquid with suitable dyes.
- the invention also relates to a kit, in particular sterile packaged, comprising the device according to the invention.
- the kit preferably contains at least one consumable, preferably all consumables, which are required for the production of thrombocyte-rich plasma from whole blood by means of the device according to the invention.
- the system is easy to handle and directly at the place of intervention.
- commercially available disposable articles such as syringes, cannulas, clamps, etc. are preferably used for this purpose.
- An object of the present invention is therefore also a device, in particular a kit, for obtaining plasma from whole blood which is rich in activated thrombocytes, comprising at least one agent for separating the whole blood into an erythrocyte-containing fraction and thrombocyte-containing and essentially erythrocyte-free plasma, at least one Composition for isolating the thrombocyte-containing plasma, at least one means for separating the thrombocyte-containing plasma into a thrombocyte fraction and into a supernatant from thrombocyte-poor plasma by centrifugation, at least one means for removing supernatant from thrombocyte-poor plasma, at least one means for mixing the removed thrombocyte-poor plasma, at least one means for reapplication of mixed thrombocyte-poor plasma into the thrombocyte fraction, at least one means for resuspending the platelet fraction in the reappli formulate thrombocytenarmen plasma un d / or at
- a further subject of the invention is a kit, in particular for obtaining plasma from whole blood rich in particular in activated thrombocytes, comprising the aforementioned device according to the invention and a centrifuge, in particular with centrifuge inserts adapted to the device according to the invention, in particular special centrifuge cups including equalizing vessels.
- the kit according to the invention preferably comprises a centrifuge modified for the use of the device according to the invention.
- the modification consists in particular of a special rotor and in particular four special hangers, with at least two metal cups plus metal screw caps which can each be sterilized, and at least one non-sterile metal cup including metal screw-on lid for weight compensation.
- Figure 1 shows a schematic representation of a preferred embodiment of the device according to the invention, be ⁇ standing from a formed as an elastic bag primary vessel (10) with a semicircular lower Ab ⁇ section (14) and a tapered funnel-shaped upper portion (15) with at least one to and / or discharge (11), which opens into the funnel-shaped upper section (15) of the primary vessel and at its lower end, which opens into the lumen of the primary vessel 10, a lip valve (13), that is flutter valve, carries at its upper end, outside the primary vessel, a port (12) designed as a luerlock, is provided.
- the primary vessel (10) has a Koch ⁇ line (20), which opens at the top of the funnel-shaped upper portion of the primary vessel (10).
- This transition (20) represents a closable connection between the volume of the primary vessel (10) and the volume of the secondary vessel (30).
- the elastic trans ⁇ parent transition (20) is defined by the interruption (21) Slider is formed, closed.
- the designed as an elastic bag secondary vessel (30) consists of a semicircular lower formed
- the riser (40) has an upper opening (41) and a lower opening (42).
- FIG. 2 shows a further preferred embodiment of the primary vessel (10) or secondary vessel (30) of the device according to the invention, which is designed as an elastic, flat bag.
- the bags are made of two superimposed plastic films which are cut over one another on the line (100) and are welded over the surface (101).
- Primschen ⁇ vessel (10) and secondary vessel (30) and the inlet and / or outlet lines (11, 31) with the terminals (12, 32) and the transition (20) are fixed on a support plate (60).
- Transition (20) is designed as an elastic hose and is closed by the trained as a clamping slide Unterbre ⁇ chung (21) which is slidably mounted on the support plate (60), closed by jamming.
- Figure 3 shows a preferred embodiment of the erfindungsge ⁇ MAESSEN device.
- FIG. 4 shows the embodiment according to FIG. 3, inserted into a centrifuge cup (50) made of metal.
- FIG. 5 shows the results (numbers on the ordinate in pg proteins / ml) of ELISA tests on various growth factors or cytokines in serum obtained from whole blood immediately after removal of whole blood (legend: t ⁇ ), thrombocyte-poor plasma isolated from whole blood according to the invention ( Legend: PPP) and in coagulated gel obtained according to the invention, in particular on activated platelets (legend: PRP).
- Example 1 Kit for obtaining thrombocyte-rich plasma from whole blood
- a sterilizable single-use kit is put together, which contains the following:
- the bag system according to the invention for the production of platelet concentrate (FIGS. 1 to 3, Table 1),
- All components are single-use items, packaged and gamma-sterilized and provided with sterling outer packaging as a whole.
- Tables 1 and 2 list the materials of the components used.
- Table 1 Inventive device according to FIGS. 1 to 3
- Component material, supplier
- Support plate (60) (cover) ABS Terlux 2802, green translucent
- Component Material, supplier device according to the invention (see Table 1) Butterfly cannula 1, 1 x 19 mm Closure cap: PE LL adapter: ABS transparent Wing connection head: PVC Tube: PVC 60 Sh A Cannula: ISO 638/13
- Protective hose PE Cannula 1, 1 x 40 mm connection head: PP protective cap: PP cannula: stainless steel acc. DIN EN ISO 9626
- Piston rod PP
- Piston plugs PP
- Perfusor line 1 5 m, LL male: ABS KR 2802 1, 0 x 2.7 mm Cap: PE 1 opaque
- Tube inner Layer: ND PE middle layer: EVA outer layer: PVC
- the required blood sample is taken with a 60 ml Luerlock syringe, which is charged with anticoagulation of the blood with 6 ml citrate / dextrose solution as anticoagulant (ACD-A) prior to collection.
- ACD-A anticoagulant
- the syringe is slowly filled to the 60 ml mark with whole blood. Attention is paid to bubble-free filling, so that in fact exactly 60 ml are in the syringe.
- the blood-filled syringe is slowly rocked 5 to 6 times to ensure that ACD-A is evenly distributed.
- the interruption (21) on the upper side of the support surface designed as a sliding clamp is pressed towards the center in order to close the hose. Remove the cap and connect the syringe to the red connector (12). In order to avoid confusion between the two connections on the carrier plate, the Luerlock connection for filling the whole blood is colored red.
- the contents of the syringe are filled slowly and completely via the supply / discharge line (11) into the primary container (10) designed as an elastic bag. The syringe is screwed Susing and the port (12) of the bag is closed with a new cap again.
- the bag system with the filled primary container (10) is inserted into the empty sterile centrifuge suspension, into the centrifuge cup (50). Attention is paid to the correct orientation of the carrier plate (60) of the bag system in the cup (FIG. 4).
- the centrifuge bowl (50) is closed with the associated screw cap.
- the sealed centrifuge cup is inserted into the centrifuge. The cup is held slightly inclined. After checking the correct weight balance by means of an enclosed water bottle (filled with about 30 ml of water), the centrifugation is carried out at 2500 rpm for 3 minutes. After expiration of the centrifugation, in which a separation of the cellular blood components of the liquid takes place, the centrifuge cup is carefully removed together with the bag system.
- the erythrocytes (EC) have accumulated in the lower portion of the primary vessel (10).
- the supernatant plasma and the intervening "buffy coat” (mononuclear cells, MZ) and thrombocytes are now by slowly rolling and / or spreading of the primary vessel (10) by means of a conventional detectable clamp from below via the transition (20) under
- the slide on the upper side is again pulled away from the center of the lid so that the transparent tube of the transfer line (20) is released Tube is filled at the top of the carrier plate completely filled with red blood components and possibly erythrocytes spill into the secondary vessel, the slide designed as a breaker (21) on the support plate is moved towards the center to close the transfer hose and the passage in to stop the secondary vessel.
- the secondary vessel now essentially contains the plasma component of the blood with thrombocytes and leucocytes as well as erythrocytes in a small amount. However, the platelets are still evenly distributed in the plasma and therefore not sufficiently concentrated.
- the thrombocytes (and the other cellular constituents contained in the blood) are now fractionated in the lower section of the bag as a pellet and the plasma fraction in the supernatant.
- the bag system is again inserted into the centrifuge using a second, sterile centrifuge beaker (50) and centrifuged at 3200 rpm for 15 minutes.
- the centrifuge beaker with the bag system is taken out of the centrifuge again, and via the removal connection (32) of the inlet / outlet (31) of the secondary vessel (30), the supernatant plasma ("platelet poor plasma", PPP) except for a small amount (less than about 2 ml)
- PPP platelet poor plasma
- the withdrawn low-platelet plasma is thoroughly mixed in the syringe.
- the syringe is vented and reconnected to the withdrawal port (32).
- About 4 ml of the plasma are returned to the bag.
- the plasma is mixed by gently "massaging" the elastic bag with the platelet fraction to form a uniform suspension of thrombocytes, which is then removed from the bag with a 10 ml syringe via inlet / outlet (31)
- This is rotated upon removal of the plasma upside down, so that the remaining amount collects in the tip of the in the tapered portion of the secondary vessel (30) and through the opening arranged there (41) of the manifold (40) of the inlet / outlet (31) can be taken.
- the plasma thus obtained (amount about 5 to 6 ml) is thrombocyte-rich plasma ("platelet rieh plasma", PRP).
- the thrombocyte-rich plasma contained in the sampling syringe (amount approx. 5-6 ml) will be coagulated by adding 1 mMO% calcium gluconate solution.
- the end product obtained is about 6 to 7 ml of thrombocyte-rich gel, which is characterized by a high content of various growth factors (FIG. 5) and can be supplied to various applications.
- thrombin bovine thrombin
- thrombin causes a rapid crosslinking of the fibrin, which among other things leads to a better An ⁇ adhesion of the gel to injured tissue and thus to a verbes ⁇ serten applicability of the thrombocyte-rich gel.
- Figure 5 shows the results of the ELISA tests.
- FIG. 5 shows that in particular the growth factors PDGF 1 TGF- ⁇ , HGF, FGF-II and IL-1ra in platelet-rich plasma are greatly increased in their concentration (pg proteins / ml) (logarithmic representation on FIG Ordinate). IGF-1 is also significantly increased in its concentration (logarithmic representation). In contrast, TNF- ⁇ and IL-1 ⁇ are scarcely elevated in their concentration.
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Pathology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05763546A EP1773426A2 (de) | 2004-07-29 | 2005-07-29 | Verfahren und mittel zur gewinnung von thrombocytenreichem plasma |
AU2005268914A AU2005268914A1 (en) | 2004-07-29 | 2005-07-29 | Method and means for obtaining platelet rich plasma |
US11/658,210 US20080286379A1 (en) | 2004-07-29 | 2005-07-29 | Method and Means for Obtaining Platelet-Rich Plasma |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102004036840.6 | 2004-07-29 | ||
DE102004036840A DE102004036840B4 (de) | 2004-07-29 | 2004-07-29 | Verfahren und Mittel zur Gewinnung von thrombocytenreichem Plasma |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006013069A2 true WO2006013069A2 (de) | 2006-02-09 |
WO2006013069A3 WO2006013069A3 (de) | 2006-06-22 |
Family
ID=35170095
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2005/008252 WO2006013069A2 (de) | 2004-07-29 | 2005-07-29 | Verfahren und mittel zur gewinnung von thrombocytenreichem plasma |
Country Status (5)
Country | Link |
---|---|
US (1) | US20080286379A1 (de) |
EP (1) | EP1773426A2 (de) |
AU (1) | AU2005268914A1 (de) |
DE (1) | DE102004036840B4 (de) |
WO (1) | WO2006013069A2 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8309343B2 (en) | 2008-12-01 | 2012-11-13 | Baxter International Inc. | Apparatus and method for processing biological material |
DE102009040525B4 (de) | 2009-09-08 | 2015-02-05 | Andreas Hettich Gmbh & Co. Kg | Zentrifuge zum Trennen von Vollblut in Blutkomponenten, sowie fluidisch kommunizierende Behälter zum Einsetzen in die Zentrifuge, sowie Verfahren zur Gewinnung eines hochangereichten Thrombozytenkonzentrats aus Vollblut |
DE202009017772U1 (de) | 2009-12-10 | 2011-04-21 | Orthogen Ag | Kombinationspräparate mit Cytokin-Antagonist und Corticosteroid |
US8808978B2 (en) | 2010-11-05 | 2014-08-19 | Haemonetics Corporation | System and method for automated platelet wash |
DE102012019088A1 (de) | 2012-09-28 | 2014-04-03 | Orthogen Ag | Antibakterielle Arzneimittelpräparate |
JP6256352B2 (ja) * | 2012-12-13 | 2018-01-10 | 株式会社ジェイ・エム・エス | 血液成分分離収容装置及び多血小板血漿の調製方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000054825A1 (en) * | 1999-03-15 | 2000-09-21 | Implant Innovations, Inc. | Platelet collection system |
WO2000061256A1 (en) * | 1999-04-12 | 2000-10-19 | Harvest Technologies Corporation | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
US20030103960A1 (en) * | 1999-12-22 | 2003-06-05 | Pierre Philippart | Sealant and bone generating product |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000062828A1 (en) * | 1996-04-30 | 2000-10-26 | Medtronic, Inc. | Autologous fibrin sealant and method for making the same |
-
2004
- 2004-07-29 DE DE102004036840A patent/DE102004036840B4/de not_active Expired - Fee Related
-
2005
- 2005-07-29 EP EP05763546A patent/EP1773426A2/de not_active Withdrawn
- 2005-07-29 AU AU2005268914A patent/AU2005268914A1/en not_active Abandoned
- 2005-07-29 US US11/658,210 patent/US20080286379A1/en not_active Abandoned
- 2005-07-29 WO PCT/EP2005/008252 patent/WO2006013069A2/de active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000054825A1 (en) * | 1999-03-15 | 2000-09-21 | Implant Innovations, Inc. | Platelet collection system |
WO2000061256A1 (en) * | 1999-04-12 | 2000-10-19 | Harvest Technologies Corporation | Method and apparatus for producing platelet rich plasma and/or platelet concentrate |
US20030103960A1 (en) * | 1999-12-22 | 2003-06-05 | Pierre Philippart | Sealant and bone generating product |
Also Published As
Publication number | Publication date |
---|---|
DE102004036840B4 (de) | 2012-04-19 |
DE102004036840A1 (de) | 2006-03-23 |
WO2006013069A3 (de) | 2006-06-22 |
AU2005268914A1 (en) | 2006-02-09 |
EP1773426A2 (de) | 2007-04-18 |
US20080286379A1 (en) | 2008-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210346587A1 (en) | New standardizations & medical devices for the preparation of platelet rich plasma (prp) or bone marrow concentrate (bmc) alone or in combination with hyaluronic acid | |
US10342552B2 (en) | Bone fragment and tissue processing system | |
DE102006005016A1 (de) | Konditionierte Blutzusammensetzung und Verfahren zu deren Herstellung | |
EP2164541A2 (de) | Flüssigkeitskonzentrator, autologe konzentrierte körperflüssigkeiten und ihre verwendungen | |
US8349189B2 (en) | Method for the preparation of at least one compound from blood, and extraction device for use in the execution of said method | |
HUE033098T2 (en) | Process, tube and device for preparing a wound healing composition | |
WO2006013069A2 (de) | Verfahren und mittel zur gewinnung von thrombocytenreichem plasma | |
US10456500B2 (en) | Implantable preparations for regeneration of tissues and treatment of wounds, their method of preparation, and method of treatment of patients with said implantable preparations | |
US11931087B2 (en) | Bone fragment and tissue processing system | |
US20200222601A1 (en) | Blood separation method | |
CN1583213A (zh) | 一种制备血小板富集血浆的装置及制备方法 | |
EP1744776B1 (de) | Wundheilungsfördernde botenstoffmischung | |
CN113332312B (zh) | 一种基于物理整粒的自成形血小板纳米囊泡及其制备方法 | |
TWM589033U (zh) | 血液分離組件及血液分離管 | |
DE102013003326A1 (de) | Verfahren zur sterilen, hilfsstofffreien Gewinnung, Separation und Anreicherung von Blutplättchen und Fibrin aus dem Vollblut | |
Sriworakun et al. | Component of manual preparation of platelet-rich plasma | |
EP4366793A1 (de) | Verfahren zur herstellung eines ein kompositmaterial aufweisenden augmentats zum ersatz oder aufbau verloren gegangener knochensubstanz | |
DE202004004571U1 (de) | In-Vitro-Vorrichtung zur Herstellung von aktivem, an Thrombozytenwachstumsfaktoren reichem menschlichen Thrombin | |
JP2018145169A (ja) | 多血小板血漿をゲル化させるゲル化方法、及びゲル化方法に用いられるキット | |
DE102006046959A1 (de) | Verfahren zur Herstellung eines Thrombozytenkonzentrats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005763546 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11658210 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005268914 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2005268914 Country of ref document: AU Date of ref document: 20050729 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005268914 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005763546 Country of ref document: EP |